Udo Kaisers

Inhaled endothelin A antagonist improves arterial oxygenation in experimental acute lung injury

Published online: 21 November 2000
© Springer-Verlag 2000

The online version of the original article can be found at
<http://dx.doi.org/10.1007/s001340000608>.

Intensive Care Med (2000) 26:1334-1342

Due to technical reasons, Table 2 was unfortunately not printed correctly. The correct table is given below:

U. Kaisers (✉) · T. Busch · S. Wolf · H. Lohbrunner · K. Wilkens · W. Boemke
Department of Anesthesiology and Operative Intensive Care
Medicine, Charité, Campus Virchow Klinikum,
Medizinische Fakultät, Humboldt-Universität,
Augustenburger Platz 1, 13353 Berlin, Germany
E-mail: udo.kaisers@charite.de
Phone: +49-30-45 05 1083
Fax: +49-30-45 05 1900

B. Hoher
Department of Nephrology, Charité, Campus Mitte,
Medizinische Fakultät, Humboldt-Universität Berlin and Institute
of Molecular Biology and Biochemistry, Freie Universität Berlin,
Germany

Table 2 Gas exchange and acid base parameters ($PaCO_2$ arterial carbon dioxide tension, SaO_2 arterial oxygen saturation, SvO_2 mixed venous oxygen saturation, PvO_2 mixed venous oxygen tension, pH_a arterial pH, $avDO_2$ difference between arterial and mixed venous oxygen content, DO_2 oxygen delivery, VO_2 oxygen consumption, ALI onset of acute lung injury)

	Protocol	Baseline	ALI	1 h	2 h	3 h	4 h	5 h	6 h
$PaCO_2$ (mmHg)	Controls	43 ± 12	52 ± 10	62 ± 17	65 ± 18	68 ± 20	70 ± 22	73 ± 24	72 ± 6§
	LU group	40 ± 14	50 ± 10	50 ± 11	48 ± 9*	46 ± 12*	51 ± 15*	50 ± 10	51 ± 11*
SaO_2 (%)	Controls	98 ± 0	79 ± 12	78 ± 10	79 ± 11	80 ± 10	76 ± 12	71 ± 15	67 ± 12
	LU group	98 ± 0	76 ± 9	89 ± 11*	95 ± 5**§	97 ± 2**§	96 ± 3**	97 ± 1**§	98 ± 1**§
SvO_2 (%)	Controls	79 ± 13	43 ± 11	45 ± 11	48 ± 14	44 ± 9	39 ± 9	33 ± 8	32 ± 7§
	LU group	76 ± 17	46 ± 14	55 ± 13	60 ± 9§	60 ± 11*	58 ± 10*	60 ± 10**§	59 ± 11**
PvO_2 (mmHg)	Controls	59 ± 17	35 ± 6	35 ± 5	37 ± 7	36 ± 5	33 ± 5	31 ± 3	30 ± 5
	LU group	53 ± 15	34 ± 7	38 ± 8	41 ± 5	40 ± 5	40 ± 7	40 ± 7**	41 ± 7**§
pH_a	Controls	7.43 ± 0.11	7.34 ± 0.09	7.31 ± 0.13	7.29 ± 0.14	7.29 ± 0.12	7.29 ± 0.12	7.27 ± 0.14	7.29 ± 0.02§
	LU group	7.46 ± 0.12	7.38 ± 0.07	7.40 ± 0.08	7.43 ± 0.06*	7.45 ± 0.06*	7.43 ± 0.08*	7.43 ± 0.07*	7.43 ± 0.06*
$avDO_2$ (ml/dl)	Controls	3.0 ± 1.3	3.0 ± 0.8	2.9 ± 0.7	2.8 ± 1.0	3.2 ± 0.8	3.5 ± 0.8	3.7 ± 1.0	3.4 ± 0.6
	LU group	3.7 ± 1.7	2.9 ± 0.7	3.5 ± 1.0	4.0 ± 0.8*	4.3 ± 1.2§	4.4 ± 1.0§	4.2 ± 0.7§	4.5 ± 1.0§
DO_2 (ml/min)	Controls	352 ± 54	286 ± 96	283 ± 108	286 ± 113	253 ± 62	257 ± 63	254 ± 86	263 ± 71
	LU group	495 ± 174*	329 ± 57	328 ± 73	329 ± 76	314 ± 74	321 ± 81	321 ± 88	323 ± 82
VO_2 (ml/min)	Controls	103 ± 36	125 ± 40	115 ± 45	108 ± 50	116 ± 45	126 ± 44	137 ± 54	133 ± 34
	LU group	146 ± 45	126 ± 30	131 ± 46	131 ± 26	123 ± 19	131 ± 25	130 ± 25	135 ± 28

* $p < 0.05$ vs. respective period in controls, ** $p < 0.01$ vs. respective period in controls, § $p < 0.05$ vs. ALI